These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17132474)

  • 1. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
    Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV
    Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
    Saltzstein L
    Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
    Wang AC; Chih SY; Chen MC
    Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder.
    Homma Y; Uemura S
    BJU Int; 2004 May; 93(7):1009-13. PubMed ID: 15142153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal oxybutynin: a new treatment for overactive bladder.
    Davila GW
    Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.
    Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW;
    J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
    Nelken RS; Ozel BZ; Leegant AR; Felix JC; Mishell DR
    Menopause; 2011 Sep; 18(9):962-6. PubMed ID: 21532512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
    Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
    Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
    Staskin DR; Robinson D
    Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin.
    Newman DK
    Director; 2008; 16(1):22-5. PubMed ID: 19343871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
    Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
    J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.